Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Open accessThe DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitumor immunity elicited by anti-PD1. Here, we observed antitumor activity following combinatorial therapy with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor models. Dinaciclib induced a type I IFN gene signature within the tumor, leading us to hypothesize that dinaciclib potentiates the effects of anti-PD1 by eliciting ICD. Indeed, tumor cells treated with dinaciclib showed the hallmarks of ICD including surface calreticulin expression and release of high mobility group box 1 (HMGB1) and ATP. Mice treated with both anti-PD1 and dinaciclib showed increased T cell infiltration and DC activation within the tumor, indicating that this combination improves the overall quality of the immune response generated. These findings identify a potential mechanism for the observed benefit of combining dinaciclib and anti-PD1, in which dinaciclib induces ICD, thereby converting the tumor cell into an endogenous vaccine and boosting the effects of anti-PD1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“dinaciclib promotes immunogenic cell death (ICD) along with robust type I IFN signaling (and despite PD-L1 upregulation in this setting) in mouse models of colorectal cancer (CRC), ultimately favoring dendritic cell (DC) activation and recruitment of CD8 + T cells that can be actioned with ICIs specific for PD-1”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hossain et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Cited by
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
“However, dinaciclib inhibits tumor growth in combination with anti-PD-1 (82).”
Pharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 287
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang, M., Zhang, L., Hei, R., Li, X., Cai, H., Wu, X., Zheng, Q., & Cai, C. (2021) · PubMed Central · Cited by 397
cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253
“Recent studies have shown that the CDK inhibitors abemaciclib and dinaciclib can potentiate antitumor immunity and enhance the efficacy of checkpoint blockade (16, 48).”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Sun, D., Zou, Y., Song, L., Han, S., Yang, H., Chu, D., Dai, Y., Ma, J., O'Driscoll, C. M., Yu, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.005 · Cited by 196
Liu, R., An, Y., Jia, W., Wang, Y., Wu, Y., Zhen, Y., Cao, J., & Gao, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.043 · Cited by 175
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
Rosenbaum, S. R., Wilski, N. A., & Aplin, A. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0805 · Cited by 171
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Rapoport, B. L., & Anderson, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040959 · Cited by 165
“Nonsteroidal anti-inflammatory drugs: Induce endoplasmic reticulum stress associated with death receptor signaling and BID activation [116] LTX-315: a cationic amphiphilic, membrane-disruptive, chemically-modified 9-mer peptide [117,118] CBP501: a calmodulin-binding peptide that promotes uptake of cisplatin into tumor…”
BackgroundInfluentialAn, J., Zhang, K., Wang, B., Wu, S., Wang, Y., Zhang, H., Zhang, Z., Liu, J., & Shi, J. (2020) · ACS Nano · doi:10.1021/acsnano.0c03881 · Cited by 148
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Jiang, Y., Zhang, H., Wang, J., Chen, J., Guo, Z., Liu, Y., & Hua, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01405-9 · Cited by 157
“The CDK inhibitor dinaciclib induces type I IFNs expression and synergizes with PD1 or PD-L1 blockade to inhibit cancer [276, 277].”
BackgroundWernitznig, D., Kiakos, K., Del Favero, G., Harrer, N., Machat, H., Osswald, A., Jakupec, M. A., Wernitznig, A., Sommergruber, W., & Keppler, B. K. (2019) · Metallomics · doi:10.1039/c9mt00051h · Cited by 136
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Peng, Q., Liu, Z.-X., Li, C., Kroemer, G., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-320441 · Cited by 119
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02043-0 · Cited by 114
“As previously reported [25, 36], aPD1 alone was more effective in MC38 tumors, which have a higher mutational load than CT26 tumors [25, 37].”
BackgroundProteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
McGrail, D. J., Garnett, J., Yin, J., Dai, H., Shih, D. J. H., Lam, T., Li, Y., Sun, C., Li, Y., Schmandt, R. E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.011 · Cited by 120
Zhou, L., Xu, Q., Huang, L., Jin, J., Zuo, X., Zhang, Q., Ye, L., Zhu, S., Zhan, P., Ren, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.049 · Cited by 111
Perry, J. A., Shallberg, L., Clark, J. T., Gullicksrud, J. A., DeLong, J. H., Douglas, B. B., Hart, A. P., Lanzar, Z., O’Dea, K., Konradt, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01170-w · Cited by 101
Chen, G., Xu, Q., Feng, Z., Xu, Q., Zhang, X., Yang, Y., Zhang, Y., Liang, X., Yu, Z., & Yu, M. (2022) · ACS Nano · doi:10.1021/acsnano.1c08544 · Cited by 102
Li, Y., Zhang, H., Li, Q., Zou, P., Huang, X., Wu, C., & Li, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.011 · Cited by 117
Zhu, Z., McGray, A. R., Jiang, W., Lu, B., Kaliński, P., & Guo, Z. S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01664-z · Cited by 116
Emerging role of immunogenic cell death in cancer immunotherapy
Arimoto, K., Miyauchi, S., Liu, M., & Zhang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390263 · Cited by 117
Zhou, H., Tu, C., Yang, P., Li, J., Kepp, O., Li, H., Zhang, L., Zhang, L., Zhao, Y., Zhang, T., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2057892 · Cited by 96
The Role of High Mobility Group Box 1 in Ischemic Stroke
Ye, Y., Zeng, Z. R., Jin, T., Zhang, H., Xiong, X., & Gu, L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00127 · Cited by 100
“including systemic lupus erythematosus (SLE), acute liver failure (ALF), tumors, and cerebrovascular diseases (Cully, 2013; Majumdar et al., 2013; Jian et al., 2016; Xiong et al., 2016; Seidu et al., 2017; Hossain et al., 2018).”
BackgroundQiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1848 · Cited by 93
Nano-enabled colorectal cancer therapy
Pan, Q., Xi, F., Xie, L. W., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.014 · Cited by 93
HMGB1 in the interplay between autophagy and apoptosis in cancer
Chen, R., Zou, J., Zhong, X. Y., Li, J., Kang, R., & Tang, D. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216494 · Cited by 87
Wu, H., Wei, G., Luo, L., Li, L., Gao, Y., Tan, X., Wang, S., Chang, H., Liu, Y., Wei, Y., et al. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00329-8 · Cited by 86
“Supernatants of 4T1 cells were collected to analyze ATP and HMBG1 levels according to the manufacturer’s instructions [27].”
MethodImmunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 80
“Besides, some ICD inducers can function in synergy with other types of immunotherapy, such as immune checkpoint inhibitors therapy [20] to enhance their effectiveness.”
BackgroundLin, C., Ren, W., Luo, Y., Li, S., Chang, Y., Li, L., Xiong, D., Huang, X., Xu, Z., Zeng, Y., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0628 · Cited by 71
“The importance of presentation by DCs in initiating a durable T-cell response has previously been demonstrated (36, 37), and in situ aMPD-1 scFv expression may enhance tumor-antigen–specific T-cell responses by promoting efficient presentation of antigens to T cells.”
BackgroundYin, M., Dong, J., Sun, C., Liu, X., Liu, Z., Liu, L., Kuang, Z., Zhang, N., Xiao, D., Zhou, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202206737 · Cited by 84
To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response
Liu, Q., Gao, J., Zhao, C., Guo, Y., Wang, S., Shen, F., Xing, X., & Luo, Y. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102702 · Cited by 68
Liu, P., Chen, J., Zhao, L., Hollebecque, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093518 · Cited by 71
Cai, J., Hu, Y., Ye, Z., Ye, L., Gao, L., Wang, Y., Sun, Q., Tong, S., Yang, J., & Chen, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011757 · Cited by 61
“Studies have shown that ICD can improve antitumour immune efficacy in combination with immune checkpoints (18).”
BackgroundCDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 72
Xu, M., Lu, J., Zhong, Y., Jiang, J., Shen, Y., Su, J., & Lin, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.870914 · Cited by 73
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 59
“The cyclin-dependent kinase inhibitor dinaciclib, which is able to induce ICD, also triggers the expression of type I IFN and MHC class I gene expression and Ccl5, Cxcl10 and Ccl2 [50].”
BackgroundElzoghby, A. O., Samir, O., Emam, H. E., Soliman, A., Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., & Nasr, M. L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.022 · Cited by 58
“Similar ICD inducing effects were reported for the histone deacetylase inhibitor, vorinostat 175 and the cyclin-dependent kinase inhibitor, dinaciclib 176 .”
BackgroundUnderstanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia
Śniegocka, M., Liccardo, F., Fazi, F., & Masciarelli, S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100853 · Cited by 58
Jin, X., Jin, W., Tong, L., Zhao, J., Zhang, L., & Lin, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.020 · Cited by 64
“Dinaciclib is a CDK inhibitor that has been found to expose CRT with increased ATP and HMGB1 to trigger ICD, improving immunotherapy in solid tumors 439 .”
Regulation of immunogenic cell death and potential applications in cancer therapy
Fang, K., Yuan, S., Zhang, X., Zhang, J., Sun, S., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571212 · Cited by 67
“Studies indicate that immune cells near to tumor tissue exhibit strong immunogenicity and in fi ltrate the tumor, transforming it into a “ hot tumor ” , and inducing tumor cells to undergo immunogenic cell death (ICD), which seems to be an effective means to enhance tumor therapy (5, 6).”
Ma, Z., Li, Z., Mao, Y., Ye, J., Liu, Z., Wang, Y., Wei, C., Cui, J., Liu, Z., & Liang, X. (2023) · Nature Communications · doi:10.1038/s41467-023-41218-5 · Cited by 63
“The sequences of the primers are listed in Supplementary Table 8.”
An emerging role for nanomaterials in increasing immunogenicity of cancer cell death
Mishchenko, T. A., Mitroshina, Е. V., Balalaeva, I. V., Krysko, O., Vedunova, M. V., & Krysko, D. V. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.004 · Cited by 55
Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy
Chen, Z., Yue, Z., Yang, K., Shen, C., Cheng, Z., Zhou, X., & Li, S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300882 · Cited by 62
Wang, L., Bi, S., Li, Z., Liao, A., Li, Y., Yang, L., Zhou, X., Gao, Y., Liu, X., Zou, Y., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122766 · Cited by 56
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Jhaveri, K. L., Burris, H. A., Yap, T. A., Hamilton, E. P., Rugo, H. S., Goldman, J. W., Dann, S. G., Liu, F., Wong, G. Y., Krupka, H. I., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944109 · Cited by 61
“Dinaciclib induces immunogenic cell death with modulation of the immune microenvironment [31], prompting com-”
Grimaldi, A., Cammarata, I., Martire, C., Focaccetti, C., Piconese, S., Buccilli, M., Mancone, C., Buzzacchino, F., Berrìos, J. R. G., D’Alessandris, N., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0811-x · Cited by 53
Cholesterol Metabolism in Cancer and Cell Death
Chen, F., Lu, Y., Lin, J., Kang, R., & Liu, J. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0340 · Cited by 53
Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. S., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01379-y · Cited by 55
“4g), and, in vaccination studies 46 , only a subset of mice in both EMT6 and E0771 models rejected the tumor after re-challenge (Fig.”
Wang, J., Zhang, Z., Zhuo, Y., Zhang, Z., Chen, R., Li, L., Jiang, X., Nie, D., Liu, C. X., Zou, Z., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.010 · Cited by 53
Riess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C.-F., Große-Thie, C., Junghanß, C., & Maletzki, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09940-4 · Cited by 50
“Abemaciclib [93, 96] CDK4/6 - Boosted antitumor immunity by enhanced antigen presentation - MHC class I/II upregulation - Selective suppression of regulatory T cells Yes”
BackgroundJin, X., Fang, R., Fan, P., Lipeng, Z., Zhang, B., Lu, X., & Liu, T. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1466-7 · Cited by 54
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy
Yu, S., Xiao, H., Ma, L., Zhang, J., & Zhang, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188946 · Cited by 53
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 50
Zhu, S., Al‐Mathkour, M. M., Cao, L., Khalafi, S., Chen, Z., Poveda, J., Peng, D., Lu, H., Soutto, M., Hu, T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112005 · Cited by 43
Ye, J., Mills, B. N., Zhao, T., Han, B. J., Murphy, J. D., Patel, A. P., Johnston, C. J., Lord, E. M., Belt, B. A., Linehan, D. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0373 · Cited by 45
“DC phagocytosis CD11cþDCs were generated fromC57BL/6J bonemarrow (BM) as described previously (24).”
MethodTargeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity
Yin, P., Gui, L., Wang, C., Yan, J., Liu, M., Ji, L., Wang, Y., Ma, B., & Gao, W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.005 · Cited by 47
Tibes, R., & Bogenberger, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01205 · Cited by 44
“When dinaciclib was combined with an anti-PD-1 antibody, T-cell and APC activation within the tumor was increased, and antitumor efficacy was improved as compared with either monotherapy (188).”
BackgroundGregory, G. P., Kumar, S. K., Wang, D., Mahadevan, D., Walker, P., Wagner‐Johnston, N. D., Escobar, C., Bannerji, R., Bhutani, D., Chang, J. E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005872 · Cited by 41
“Median (range) 50 (1-492) 51 (1-471) 29 (8-71) 49 (1-492)”
BackgroundHan, J., Cai, M., Grein, J., Perera, S. A., Wang, H., Bigler, M., Ueda, R., Rosahl, T. W., Pinheiro, E. M., LaFace, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573405 · Cited by 40
“A shown in Figure 1, we began treatment of MC38 tumor-bearing mice with anti-TIGIT: mIgG2a and anti-TIGIT:mIgG1∗ as single agents, or in combination with anti-PD-1 when the tumor size was on average 190 mm3 (Figures 1A,B).”
BackgroundMethodInfluentialKe, C., Hou, H., Li, J., Su, K., Huang, C., Lin, Y., Lu, Z., Du, Z., Tan, W., & Yuan, Z. (2020) · Cancers · doi:10.3390/cancers12051157 · Cited by 38
“Dinaciclib was previously shown to increase T cell infiltration and DC activation within mice tumors by eliciting immunogenic cell death (ICD) when combined with anti-PD1 therapy [26].”
BackgroundImmunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system
Calvillo‐Rodríguez, K. M., Lorenzo-Anota, H. Y., Rodríguez-Padilla, C., Martínez‐Torres, A. C., & Scott‐Algara, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294434 · Cited by 46
Autophagy regulation as a promising approach for improving cancer immunotherapy
Ishimwe, N., Zhang, W., Qian, J., Zhang, Y., & Wen, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.034 · Cited by 37
CDK12: a potential therapeutic target in cancer
Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 37
CDK9 inhibitors in cancer research
Huang, Z. L., Wang, T., Wang, C., & Fan, Y. L. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00040g · Cited by 36
Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy
Sun, D., Zhang, J., Wang, L., Yu, Z., O’Driscoll, C. M., & Guo, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.029 · Cited by 34
Ghiringhelli, F., & Rébé, C. (2023) · Immunological Reviews · doi:10.1111/imr.13263 · Cited by 40
“…produced during ICD: CXCL2, 3, 5, 6, CCL20 (mitomycin C on bladder cancer cell lines), 30 CXCL16 (radiations on human and murine cancer cell lines), 31,32 CCL2 (paclitaxel), 33 Ccl5 , Cxcl10 , and Ccl2 ( cyclin-dependent kinase inhibitor, dinaciclib), 34 or CXCL11 (docetaxel on human NSCLC cells).”
PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC
Zhou, J. H. S., Yang, Q., Lu, L., Tuo, Z., Shou, Z., & Cheng, J. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.60135 · Cited by 38
Wang, M., Hu, Q., Huang, J., Zhang, F., Yao, Z., Shao, S., Zhao, X., & Liang, T. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203264 · Cited by 38
Long, Z., Hua, X., Zhang, W., Lv, S., Deng, J., Guo, L., He, Z., & Lin, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200759 · Cited by 31
“Immunotherapeutic drugs such as PD-1 inhibitors could provide a good therapeutic response in these patients.(25) Furthermore, those patients with low-AAPR status should have their cancer status and physical condition reviewed more carefully compared with the high-AAPR group.”
BackgroundZhang, S., Liu, N., Ma, M., Huang, H., Handley, M., Bai, X., & Shan, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107837 · Cited by 31
Mehlich, D., & Marusiak, A. A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215775 · Cited by 37
BH3 Mimetics in AML Therapy: Death and Beyond?
Cerella, C., Dicato, M. A., & Diederich, M. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.004 · Cited by 34
Targeting CDK9 for the Treatment of Glioblastoma
Ranjan, A., Pang, Y. K., Butler, M. K., Merchant, M., Kim, O., Yu, G., Su, Y., Gilbert, M. R., Levens, D., & Wu, J. (2021) · Cancers · doi:10.3390/cancers13123039 · Cited by 31
“Zotiraciclib was also shown to suppress glycolysis, resulting in depleted intracellular ATP levels, and combination treatment of zotiraciclib and TMZ demonstrated a synergistic effect through further glycolytic suppression, as observed by the downregulation of the glycolytic enzymes Hexokinase 2 (HK2), Pyruvate Kinase…”
BackgroundResultInfluentialMa, Y., Li, J., Zhao, Y., Hu, B., Liu, Y., & Liu, C. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.10.017 · Cited by 28
Skaličková, M., Vanova, K. H., Uher, O., Fialová, J. L., Petrláková, K., Masařík, M., Kejík, Z., Martasek, P., Pacák, K., & Jakubek, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479483 · Cited by 29
Bauché, D., Mauze, S., Kochel, C. M., Grein, J., Sawant, A., Zybina, Y., Blumenschein, W. M., Yang, P., Annamalai, L., Yearley, J. H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001584 · Cited by 29
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 36
Orhan, E., Velázquez, C., Tabet, I., Fenou, L., Rodier, G., Orsetti, B., Jacot, W., Sardet, C., & Theillet, C. G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216820 · Cited by 33
Gui, L., Chen, K., Yan, J., Chen, P., Gao, W., & Ma, B. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101913 · Cited by 48
“9 However, a systemic evaluation of kinase targets, whose inhibition leads to ICD, is still lacking.”
Current progress and novel strategies that target CDK12 for drug discovery
Lei, P., Zhang, J., Liao, P., Ren, C., Wang, J., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114603 · Cited by 27
Targeting acid ceramidase enhances antitumor immune response in colorectal cancer
Vijayan, Y., James, S., Viswanathan, A. (., Aparna, J. S., Bindu, A., Namitha, N. N., Anantharaman, D., Lankadasari, M. B., & Harikumar, K. B. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.12.013 · Cited by 32
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
Maines, L. W., Keller, S. N., & Smith, C. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316901 · Cited by 26
Hallaj, S., Asl, S. H., Alian, F., Farshid, S., Eshaghi, F. S., Namdar, A., Atyabi, F., Masjedi, A., Hallaj, T., Ghorbani, A., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118150 · Cited by 25
RetractedZolekar, A., Lin, V. J. T., Mishra, N. M., Ho, Y. Y., Hayatshahi, H. S., Parab, A., Sampat, R., Liao, X., Hoffmann, P., Liu, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0265-9 · Cited by 28
Dendritic cells: the yin and yang in disease progression
Jiménez‐Cortegana, C., Palomares, F., Álba, G., Santa‐María, C., de la Cruz‐Merino, L., Sánchez‐Margalet, V., & López-Enríquez, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1321051 · Cited by 32
Yang, R., Bei, W., Su, Z., Song, Y., Zhang, Y., Liu, Y., Zhang, Y., He, C., Xi, Y., Zhong, F., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn6921 · Cited by 26
Li, S., Zhu, W., Ye, C., Sun, W., Xie, H., Yang, X., Zhang, Q., & Ma, Y. (2020) · Nanoscale · doi:10.1039/c9nr10334a · Cited by 23
Drug Delivery for Cancer Immunotherapy and Vaccines
Batty, C. J., Tiet, P., Bachelder, E. M., & Ainslie, K. M. (2018) · Pharmaceutical Nanotechnology · doi:10.2174/2211738506666180918122337 · Cited by 26
“The chemotherapeutics that have been identified as inducers of ICD include doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide, oxaliplatin, patupilone, and dinaciclib [33, 34].”
BackgroundCharacterization of immune cell populations in syngeneic murine tumor models
Snipstad, S., Bremnes, F., Haugum, M. D., & Sulheim, E. (2023) · Cancer Medicine · doi:10.1002/cam4.5784 · Cited by 26
CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
Cheung, A., Chenoweth, A. M., Quist, J., Sow, H. S., Malaktou, C., Ferro, R., Hoffmann, R. M., Osborn, G., Sachouli, E., French, E., et al. (2022) · Cancers · doi:10.3390/cancers14143361 · Cited by 23
“checkpoint immunotherapy resulted in an enhanced anti-tumor response [75].”
BackgroundTargeting VCP potentiates immune checkpoint therapy for colorectal cancer
Wang, F., Qi, Q., Qin, B., Wang, Y., Huang, Y., Li, Q., Shen, X. H., Wang, X., Yang, S., Pan, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113318 · Cited by 24
Ding, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.052 · Cited by 24
Immunogenic cell death: A link between gut microbiota and anticancer effects
Chen, W., Wang, S., Wu, Y., Shen, X., Guo, Z., Li, Q., & Xing, D. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.103983 · Cited by 22
Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells
Grazia, A. D., Laudisi, F., Fusco, D. D., Franzè, E., Ortenzi, A., Monteleone, I., Monteleone, G., & Stolfi, C. (2020) · Cancers · doi:10.3390/cancers12051314 · Cited by 23
“In support of this expectation are recent studies showing that the anti-helmintic drug niclosamide and the CDK inhibitor dinaciclib enhanced the e ffi cacy of PD-1 / PD-L1 immune checkpoint blockade in non-small cell lung cancer and colon adenocarcinoma, respectively [47,48].”
Metadata
- Authors
- Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., & Chackerian, A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Chackerian, Alissa
- Venue
- Journal of Clinical Investigation
- Published
- 2018-01-16
- Volume
- 128
- Issue
- 2
- Pages
- 644-654
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5785250
- OpenAlex
- W2783507731
- Cited by
- 216
- References
- 88
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 37 · 2023: 45 · 2022: 29 · 2021: 22 · 2020: 32 · 2019: 11 · 2018: 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dinaciclib, immunogenic cell death, anti-PD-1 therapy, combination cancer immunotherapy, cyclin-dependent kinase inhibitors, type I interferon signature, calreticulin, HMGB1, ATP release, T cell infiltration, tumor immunogenicity, cancer vaccines
- MeSH terms
- Adenocarcinoma, Adenosine Triphosphate, Animals, Antibodies, Monoclonal, Cyclic N-Oxides, Dendritic Cells, Drug Synergism, Female, Immune System, Immunotherapy, Indolizines, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Transplantation, Phagocytosis, Pyridinium Compounds, Cytokines, Cell Death, Apoptosis, Mice, Knockout, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, HMGB1 Protein, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.